OOIR: Observatory of International Research

Papers

(The TQCC of mAbs is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Tokenizing loops of antibodies	260
Correction	165
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	161
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	141
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	139
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	129
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	94
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	92
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	90
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	89
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	86
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	80
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	68
Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics	66
An antibody developability triaging pipeline exploiting protein language models	61
Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma	60
Correction	55
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	55
The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies	51
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	51
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	50
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs	48
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	45
Impact of IgG subclass on monoclonal antibody developability	45
Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates	44

Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	43
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	43
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	40
Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection	38
A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology	38
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	37
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	35
Antibodies to watch in 2024	34
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	34
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	33
Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG ₁ antibody	32
Higher order receptor clustering due to the IgG3 subclass is necessary for TLR4 signaling and tolerance induction by novel human anti-TLR4 antibodies	32
Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutions	31
A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHO	30
Temperature and excipient mediated modulation of monoclonal antibody interactions revealed by k D, rheology, and Raman spectroscopy	29
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production	29
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice	28
Discovery of broadly neutralizing V _H Hs against short-chain α-neurotoxins using a consensus toxin as an antigen	28
Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan	28
Quantifying antibody binding: techniques and therapeutic implications	28
Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment	27
Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing	27
Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications	27
Correction	26
Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab	26
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies	26
Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L	26
Building a potent TREM2 agonistic, biparatopic, common light chain antibody	26
Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches	25
Antibodies to watch in 2026	24
Evolution of phage display libraries for therapeutic antibody discovery	24
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier	24
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies	24
Cost and supply considerations for antibody therapeutics	24
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	23
Balancing brain exposure, pharmacokinetics and safety of transferrin receptor antibodies for delivery of neuro-therapeutics	23
Electrostatic properties of human germlines and biodistribution of small biologics	23
Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality	22
Impact of process parameters on IgG glycosylation in CHO systems: a comprehensive quantitative analysis	22
A glyco-engineering approach for site-specific conjugation to Fab glycans	22
A versatile design platform for glycoengineering therapeutic antibodies	22
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge	22
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties	21
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	21
Antigenic landscapes on Staphylococcus aureus pore-forming toxins reveal insights into specificity and cross-neutralization	21
A comprehensive strategy for pandemic preparedness with neutralizing monoclonal antibodies	21
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation	21
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue	21
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	20
Efficient production of bispecific antibody by FAST-Ig ^TM and its application to NXT007 for the treatment of hemophilia A	20

Engineering death resistance in CHO cells for improved perfusion culture	20
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	20
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG ₁ antibodies	19
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	19
Leveraging multi-modal feature learning for predictions of antibody viscosity	19
Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies	18
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows	18
Structural and biochemical differences between non-catalytic and catalytic antibodies	18
Impact of process impurities on developability assessments of complex antibody formats: the striking role of leachable copper	18
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function	18
Multidimensional maturation of antibody variable domains with machine-learning assistance	18
Predicting purification process fit of monoclonal antibodies using machine learning	18
Reduction of monoclonal antibody viscosity using interpretable machine learning	18
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	18
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach	17
Structure–function analysis of empasiprubart, a calcium- and pH-dependent clinical phase complement C2 blocking antibody	16
Coactivation of Tie2 and Wnt signaling using an antibody–R-spondin fusion potentiates therapeutic angiogenesis and vessel stabilization in hindlimb ischemia	16
A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects	16
Combining deep mutational scanning and SPR binning approaches for large-scale epitope identification of anti-ricin antibodies	16
Development of a PRAME pMHC targeted T cell engager for solid tumor therapy	16
Physics-based surface patch analysis for prediction of hydrophobic contribution to viscosity of mAbs	16
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1	16
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	15
Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1	15
Alpseq : an open-source workflow to turbocharge nanobody discovery with high-throughput sequencing	15
Structures of clinical antibodies bound to IL-33 uncover two distinct epitopes underlying differential efficacy	14
A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties	14
Antibody markup language (AbML) — a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw)	14
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process	14
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers	14
The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity	13
2D NMR assessment of structural consistency and functional relationships in monoclonal antibodies	13
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors	13
Determination of ultra-trace metal-protein interactions in co-formulated monoclonal antibody drug product by SEC-ICP-MS	13
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows	13
Correction	13
Understanding the structure–property relationship of bispecific monoclonal antibodies with Fc site-specific substitutions	13
NAb-seq: an accurate, rapid, and cost-effective method for antibody long-read sequencing in hybridoma cell lines and single B cells	13